8-K: Co-Diagnostics Reports 2025 Results Amid Strategic Global Expansion

Co-Diagnostics, Inc. announced full year 2025 financial results, reporting a significant revenue decline and increased net loss, while highlighting progress in global joint ventures and clinical pipeline.

Summary

• Revenue for full year 2025 was $0.6 million, a substantial decrease from $3.9 million in 2024, primarily due to lower grant revenue.
• Operating expenses increased to $50.6 million in 2025 from $43.0 million in 2024, largely driven by an $18.9 million non-cash impairment charge on intangible assets.
• The company reported an operating loss of $50.2 million in 2025, up from $40.1 million in 2024.
• Net loss for 2025 was $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share, in 2024.
• Adjusted EBITDA loss improved to $28.0 million in 2025 from $33.5 million in 2024.
• Cash, cash equivalents, and marketable investment securities decreased significantly to $11.9 million as of December 31, 2025, from $29.7 million as of December 31, 2024.
• The company completed two common stock offerings, raising $3.8 million and $7.0 million, respectively.
• Significant progress was made in the CoSara Diagnostics joint venture in India, including regulatory approval for the PCR Pro instrument and expansion of commercial territory across South Asia, increasing the addressable market to approximately $13 billion.
• A definitive agreement was signed to establish the CoMira Diagnostics joint venture in Saudi Arabia.
• Clinical evaluations for an upper respiratory multiplex test were initiated and advanced, with plans for an initial FDA 510(k) submission focused on flu A, flu B, and RSV.
• Development continued across pipeline programs, including tuberculosis (TB) and HPV tests.
• The AI business unit expanded, integrating machine learning into the Co-Dx Primer Ai platform, and new international patents were granted in Australia and Japan.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as largely negative due to the significant decline in revenue, increased net loss, and substantial cash burn, despite strategic progress in joint ventures and product development which are yet to yield commercial returns.

Positives

• Adjusted EBITDA loss improved to $28.0 million in 2025 from $33.5 million in 2024.
• Successfully closed two common stock offerings, raising a total of $10.8 million.
• CoSara Diagnostics joint venture in India achieved regulatory progress, including a CDSCO license to manufacture and sell the PCR Pro instrument.
• Expanded CoSara Diagnostics' commercial and distribution territory across South Asia (Bangladesh, Pakistan, Nepal, Sri Lanka), increasing the regional addressable market to approximately $13 billion.
• Initiated shipments of PCR Pro instruments and tuberculosis (TB) test materials to India for upcoming clinical performance studies, aligning with new WHO guidance.
• Signed a definitive agreement to establish the CoMira Diagnostics joint venture in Saudi Arabia.
• Advanced clinical evaluations of an upper respiratory multiplex test and progressed development of TB and HPV tests.
• Expanded the AI business unit, integrating machine learning capabilities into the Co-Dx Primer Ai platform.
• Strengthened the intellectual property portfolio with new international patents granted in Australia and Japan.
• Engaged Maxim Group to pursue a SPAC transaction for CoSara Diagnostics.

Negatives

• Revenue for full year 2025 significantly decreased to $0.6 million from $3.9 million in 2024, primarily due to lower grant revenue.
• Operating expenses increased to $50.6 million in 2025 from $43.0 million in 2024, largely due to an $18.9 million non-cash impairment charge from revaluation of intangible assets.
• Operating loss increased to $50.2 million in 2025 from $40.1 million in 2024.
• Net loss increased to $46.9 million in 2025 from $37.6 million in 2024.
• Cash, cash equivalents, and marketable investment securities decreased substantially to $11.9 million as of December 31, 2025, from $29.7 million as of December 31, 2024.
• The Co-Dx PCR platform and associated tests are not yet available for sale, pending regulatory review.

Risks

• The Co-Dx PCR platform (including PCR Home, PCR Pro, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale, posing a risk to commercialization timelines and revenue generation.
• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances, meaning actual results may differ materially from expectations.
• There is no assurance that any of the anticipated results, such as successful commercialization or regulatory approvals, will occur on a timely basis or at all.

Future Outlook

The company is preparing for commercialization of its platform in 2026, focusing on advancing its clinical pipeline and expanding its global footprint through joint ventures like CoSara in India and CoMira in the Middle East and Northern Africa. It plans an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV, aiming to accelerate regulatory and commercialization timelines. The company believes its progress creates a clear path to unlock the full potential of its platform in the next phase of execution in 2026.

Management Comments

• "Over the past year, we made meaningful progress across multiple initiatives that have positioned the Company for its next phase of growth, including advancing our clinical pipeline, expanding our global footprint, and preparing for commercialization of the platform in 2026."
• "Importantly, we have remained focused on execution and continued to build momentum across the business."
• "Our strategy is centered on four key pillars: advancing CoSara and our broader opportunity in India, executing on our CoMira joint venture in the Middle East and Northern Africa, progressing our clinical programs toward key regulatory milestones, and expanding our AI-driven capabilities."
• "Together, these initiatives support our scalable, globally deployable diagnostics platform and reinforce our focus on long-term value creation."
• "Based on dramatically reduced rates of COVID prevalence in our clinical study locations, we are currently planning on an initial FDA 510(k) submission for our upper respiratory test focused on flu A, flu B, and RSV."
• "This modified approach will allow us to accelerate regulatory and commercialization timelines while retaining the flexibility to incorporate COVID into the test at a later stage if conditions change."
• "We believe the progress we've made in our clinical studies and on all other initiatives are creating a clear path to unlock the full potential of our platform as we enter the next phase of execution in 2026."

Industry Context

StockSavvy.ai notes that Co-Diagnostics' strategic focus on expanding into emerging markets like India and Saudi Arabia through joint ventures aligns with a broader industry trend of increasing demand for accessible and affordable molecular diagnostics in developing regions. The shift in FDA submission strategy for the upper respiratory test, prioritizing flu A, flu B, and RSV over COVID-19, reflects the evolving landscape of infectious disease prevalence and regulatory priorities post-pandemic. The integration of AI into its Primer Ai platform also positions the company within the growing trend of leveraging artificial intelligence for enhanced diagnostic accuracy and development efficiency in the molecular diagnostics sector.

Comparison to Industry Standards

• The significant decline in revenue from $3.9 million to $0.6 million is a substantial underperformance compared to many established molecular diagnostics companies that have either maintained or grown revenue, even post-COVID-19, by diversifying their product portfolios or expanding market reach.
• The increased net loss and operating loss, coupled with a substantial non-cash impairment charge of $18.9 million on intangible assets, suggests challenges in asset valuation and profitability that are not typical for well-performing companies in the diagnostics space, which often demonstrate more stable or improving profitability metrics.
• The decrease in cash, cash equivalents, and marketable investment securities from $29.7 million to $11.9 million indicates a significant cash burn, which is a concern when compared to industry peers that typically maintain stronger liquidity positions or demonstrate a clear path to cash flow positivity.
• However, the expansion into new territories like South Asia with an estimated $13 billion addressable market, and the establishment of new joint ventures (CoSara, CoMira), are strategic moves that align with growth strategies seen in successful global diagnostics firms like Roche Diagnostics or Abbott Laboratories, which continuously seek to penetrate new high-growth markets.
• The advancement of clinical evaluations for multiplex tests and the integration of AI into the Co-Dx Primer Ai platform are competitive developments, mirroring efforts by leading diagnostic innovators to enhance product capabilities and efficiency, although the "not yet available for sale" status indicates a lag in commercialization compared to market leaders.

Stakeholder Impact

• Shareholders: Experience significant dilution from recent stock offerings and face increased net losses and a declining cash position, potentially impacting share value. However, strategic expansions and pipeline progress offer long-term growth potential if successfully commercialized.
• Employees: Continued investment in R&D and expansion of AI business unit may indicate job stability or growth in specific areas, but overall financial performance could create uncertainty.
• Customers (future): Potential for new diagnostic products (PCR Pro, upper respiratory, TB, HPV tests) in new markets (India, South Asia, Middle East) once regulatory approvals are secured.
• Suppliers: Continued operations and manufacturing readiness for PCR Pro in India suggest ongoing demand for supplies.
• Creditors: The declining cash position and increased losses could raise concerns about the company's ability to meet future obligations, although recent capital raises provide some liquidity.

Next Steps

• Continue advancing CoSara Diagnostics in India, including manufacturing readiness and commercialization.
• Progress execution and finalize lease for manufacturing facility for CoMira Diagnostics joint venture in Saudi Arabia.
• Initiate an initial FDA 510(k) submission for the upper respiratory test focused on flu A, flu B, and RSV.
• Continue progressing development across pipeline programs, including tuberculosis (TB) and HPV tests.
• Enter the next phase of execution in 2026 for the platform's full potential.
• Host a conference call and webcast on March 31, 2026, to discuss financial results.

Key Dates

Recommendation

The company reported a drastic 85% decline in revenue, a significant increase in net loss, and a substantial reduction in cash reserves. While strategic initiatives and joint ventures are underway, their commercialization is still pending regulatory approval, and the current financial performance indicates a high cash burn and lack of immediate profitability. The recent capital raises, while providing some liquidity, also resulted in significant shareholder dilution. Given the deteriorating financial health and the speculative nature of future commercial success, a seasoned investor would likely recommend selling to mitigate further losses.

Keywords

Molecular diagnostics, Co-Diagnostics, CODX, Financial results, SEC filing, PCR platform, Joint ventures, CoSara Diagnostics, CoMira Diagnostics, India, Saudi Arabia, Upper respiratory test, Tuberculosis test, HPV test, AI, Intellectual property, FDA 510(k), EBITDA, Revenue, Net loss, Cash position, Capital raise